NasdaqCM - Nasdaq Real Time Price • USD
Evogene Ltd. (EVGN)
At close: April 18 at 4:00 PM EDT
After hours: April 18 at 5:17 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 1 |
| Avg. Estimate | -0.09 | -0.12 | -0.42 | -0.33 |
| Low Estimate | -0.1 | -0.12 | -0.44 | -0.33 |
| High Estimate | -0.09 | -0.12 | -0.41 | -0.33 |
| Year Ago EPS | -0.15 | -0.17 | -0.52 | -0.42 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | 3.5M | 2.5M | 17M | 31.5M |
| Low Estimate | 3.5M | 2.5M | 17M | 31.5M |
| High Estimate | 3.5M | 2.5M | 17M | 31.5M |
| Year Ago Sales | -- | -- | 5.64M | 17M |
| Sales Growth (year/est) | -- | -- | 201.40% | 85.30% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.16 | -0.17 | -0.16 | -0.14 |
| EPS Actual | -0.15 | -0.17 | -0.08 | -0.13 |
| Difference | 0.01 | 0 | 0.08 | 0.01 |
| Surprise % | 6.30% | 0.00% | 50.00% | 7.10% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.09 | -0.12 | -0.42 | -0.33 |
| 7 Days Ago | -0.09 | -0.12 | -0.42 | -0.33 |
| 30 Days Ago | -0.09 | -0.12 | -0.42 | -0.33 |
| 60 Days Ago | -0.05 | -0.09 | -0.34 | -0.36 |
| 90 Days Ago | -0.05 | -0.09 | -0.34 | -0.36 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | EVGN | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 40.00% | -- | -- | 0.80% |
| Next Qtr. | 29.40% | -- | -- | 9.60% |
| Current Year | 19.20% | -- | -- | 4.50% |
| Next Year | 21.40% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Initiated | Alliance Global Partners: Buy | 10/2/2023 |
| Maintains | Lake Street: Buy to Buy | 8/18/2023 |
| Maintains | Roth MKM: Buy to Buy | 7/21/2023 |
| Initiated | Lake Street: Buy | 5/2/2023 |
| Maintains | Aegis Capital: Buy | 9/12/2022 |
| Maintains | Roth MKM: Buy to Buy | 9/2/2022 |
Related Tickers
CGEN Compugen Ltd.
1.8800
-1.05%
PLUR Pluri Inc.
5.05
-2.32%
CANF Can-Fite BioPharma Ltd.
1.9700
+0.51%
ENLV Enlivex Therapeutics Ltd.
1.4000
-5.41%
XTLB XTL Biopharmaceuticals Ltd.
2.4400
-1.21%
BLRX BioLineRx Ltd.
0.6401
+2.88%
ENLV.TA Enlivex Therapeutics Ltd.
545.90
-4.26%
PPBT Purple Biotech Ltd
0.4610
+2.67%
ORMP Oramed Pharmaceuticals Inc.
2.2000
-5.58%
LUMO Lumos Pharma, Inc.
2.6200
+6.50%